The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.

Activators of BAX and their uses in cancer therapy are disclosed.

The present invention discloses a hair growth stimulating system. The hair growth stimulating system includes a topical solution for application on a user's scalp with nanoparticles dispersed throughout. The nanoparticles emit red light toward the scalp to stimulate hair growth when irradiated with photons from a light source. The present invention also discloses a clothing article for hair growth stimulation that includes a head covering for overlaying a scalp of a user. The head covering has a window to allow light to pass through to the scalp. The window may have a thin film embedded with nanoparticles that emit red light toward the scalp to stimulate hair growth when irradiated with photons from a light source. Alternatively, the window has a thin film for receiving a topical solution that includes nanoparticles dispersed therein, which in turn emit red light toward the scalp to stimulate hair growth when irradiated with photons.

The present invention discloses a hair growth stimulating system. The hair growth stimulating system includes a topical solution for application on a user's scalp with nanoparticles dispersed throughout. The nanoparticles emit red light toward the scalp to stimulate hair growth when irradiated with photons from a light source. The present invention also discloses a clothing article for hair growth stimulation that includes a head covering for overlaying a scalp of a user. The head covering has a window to allow light to pass through to the scalp. The window may have a thin film embedded with nanoparticles that emit red light toward the scalp to stimulate hair growth when irradiated with photons from a light source. Alternatively, the window has a thin film for receiving a topical solution that includes nanoparticles dispersed therein, which in turn emit red light toward the scalp to stimulate hair growth when irradiated with photons.

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

The present invention relates to a new class of compounds of formula (I) having an antiviral effect and the uses thereof.

The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.

Transforming growth factor β (TGFβ) transcriptional responses are involved in the pathogenesis of aortic aneurism syndromes. Compositions that inhibit histone acetyltransferase activity normalize gene expression in the aorta, preserved aortic wall architecture and abrogated aneurism progression. Methods include the use of these compositions to epigenetically regulate abnormal expression and/or activity of TGFβ genes.

Certain compounds are lysophosphatidic acid receptor antagonists have high LPAR1 antagonist activity and selectivity, low toxicity, good metabolic stability, promising pharmaceutical development prospects, and may be used for preventing or treating LPAR1-related diseases or illnesses. The IC50 values of some of the compounds may be as low as 300 nM or below, even 50 nM or below. In addition, CC50 value range of the compounds may be as high as 200 μM or above. Furthermore, the compounds have good metabolic stability in humans, mice and rats.